Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-06-07 00:00:00 ET · period of report 2023-06-01 · accession 0001209191-23-035239 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-07 | 2023-06-01 | RXRX | Mauro David J | Chief Medical Off | A - Grant | $0.00 | +190.7K | 190.7K | New | $0 |
| D | 2023-06-07 | 2023-06-01 | RXRX | Mauro David J | Chief Medical Off | A - Grant | $0.00 | +381.4K | 381.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-06-01 | A | A | 190,713 | $0.00 | 190,713 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-06-01 | A | A | 381,426 | $0.00 | 381,426 | D | $8.77 · — to 2033-06-01 | 381,426 Class A Common Stock | (F2) This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date. |